MedTrace Logo

Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT

NCT03336385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-23

No results posted yet for this study

Summary

The investigators aim was to assess whether 6 weeks of oral intake of the wheat-derived prebiotic fiber arabinoxylan or oat-derived beta-glucan could improve intestinal barrier function against drug-induced barrier disruption in a general population of elderly people, in a randomized double blinded placebo-controlled clinical trial.

Conditions

  • Prebiotics
  • Aged

Interventions

DIETARY_SUPPLEMENT

Naxus

Non-digestible polysaccharides arabinoxylan (Naxus)

DIETARY_SUPPLEMENT

Oatwell

Non-digestible polysaccharides oat beta-glucan (Oatwell)

DIETARY_SUPPLEMENT

Placebo

Maltodextrin as placebo

Sponsors & Collaborators

  • Fibebiotics consortium (EU)

    collaborator UNKNOWN

  • Örebro University, Sweden

    lead OTHER

Principal Investigators

  • Robert J Brummer, MD, PhD · Örebro University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-12
Primary Completion
2015-12-18
Completion
2015-12-18

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336385 on ClinicalTrials.gov